Article
Primate-Specific LINC03040 Drives MASH Fibrosis via a Myeloid-Dependent Immuno-Metabolic Axis
2026-02-09
Abstract excerpt
<title>Abstract</title> <p> Background While the recent approval of resmetirom marks a historic milestone in MASH therapy, the effective reversal of established cirrhosis (F4) remains a major unmet clinical need. A critical bottleneck in developing anti-fibrotic drugs for this advanced stage is the profound translational gap between murine models and human immunopathology, particularly regarding species-specifi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1c682606-a086-5fca-90dc-6d6daca15fd5
- DOI
- 10.21203/rs.3.rs-8780157/v1
